Informations générales (source: ClinicalTrials.gov)
Dimensional and Developmental Approach to Psychotic Episodes in Children and Adolescents: Impact on Clinical Management
Interventional
N/A
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
juin 2021
octobre 2026
11 septembre 2025
Five collaborating sites in France will study the broad spectrum of schizophrenia in
children and adolescents. Patients will be studied with diagnostic interviews,
developmental histories, dimensional clinical ratings, comprehensive cognitive
assessments, neuroimaging and DNA (copy number variant) analyses (in families and
patients who agree), and follow-up of course of illness, cognitive status and treatment
response to specific antipsychotic drugs. The goal of the study is to test a prior
hypothesis about clinical subgroups in this population and to test whether these
subgroups predict antipsychotic medication response.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHS FONDATION VALLEE | LAURENT Claudine | 13/12/2025 07:42:39 | Contacter | ||
| AP-HP Assistance publique - Hôpitaux de Paris | 13/12/2025 07:42:39 | Contacter | |||
| AP-HP - Hôpital La Pitié-Salpêtrière | |||||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU de Rouvray - 76031 - Rouen - France | BISSERY Anne | 13/12/2025 07:42:39 | Contact (sur clinicalTrials) | ||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHRU de Lille - 59037 - Lille - France | Bissery Anne | Contact (sur clinicalTrials) | |||
| CHU de Nice - 62000 - Nice - France | BISSERY Anne | Contact (sur clinicalTrials) | |||
| CHU de Rouen - 76031 - Rouen - France | BISSERY Anne | Contact (sur clinicalTrials) | |||
| Fondation Vallée, Gentilly - 94257 - Gentilly - France | BISSERY Anne | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria for the Patient:
1. Children and young adults ages 7-20 years with age of onset of psychotic disorder
between 7-17 years.
2. Hospitalized or seen for out-patient treatment for a psychotic episode, acute or
chronic.
3. DSM-V diagnosis of schizophrenia, schizoaffective disorder, schizophreniform
disorder, brief psychotic disorder, psychotic disorder not otherwise specified, or
major depressive episode with psychotic features.
4. Written informed consent signed by the parents or the individual(s) with legal
parental authority, and by the minor patient if his/her condition permits.
5. Written informed consent signed by the patient if he/she is a major, after clinical
stabilization (not delusional).
6. Has health insurance coverage from Social Security (France) (not AME coverage).
Inclusion Criteria for parents or siblings wishing to participate in the genetic part of
the study :
1. Parents : no specific criteria.
2. Siblings : siblings are eligible to participate if there are at least two
first-degree relatives with psychotic disorders (including the patient) in the
family.
3. Written informed consent for the genetic part of the study signed by any
participating parents and siblings.
4. Has health insurance coverage from Social Security (France) (not AME coverage).
Exclusion Criteria:
1. Moderate or severe intellectual deficiency (IQ < 50).
2. Psychoses judged to be secondary to medical illness, medication effects or drugs of
abuse.
3. Diagnosis of bipolar disorder.
4. Patients who are under legal guardianship.
5. For the neuroimaging part of the study only : any contraindications to Magnetic
Resonance Imaging.
1. Children and young adults ages 7-20 years with age of onset of psychotic disorder
between 7-17 years.
2. Hospitalized or seen for out-patient treatment for a psychotic episode, acute or
chronic.
3. DSM-V diagnosis of schizophrenia, schizoaffective disorder, schizophreniform
disorder, brief psychotic disorder, psychotic disorder not otherwise specified, or
major depressive episode with psychotic features.
4. Written informed consent signed by the parents or the individual(s) with legal
parental authority, and by the minor patient if his/her condition permits.
5. Written informed consent signed by the patient if he/she is a major, after clinical
stabilization (not delusional).
6. Has health insurance coverage from Social Security (France) (not AME coverage).
Inclusion Criteria for parents or siblings wishing to participate in the genetic part of
the study :
1. Parents : no specific criteria.
2. Siblings : siblings are eligible to participate if there are at least two
first-degree relatives with psychotic disorders (including the patient) in the
family.
3. Written informed consent for the genetic part of the study signed by any
participating parents and siblings.
4. Has health insurance coverage from Social Security (France) (not AME coverage).
Exclusion Criteria:
1. Moderate or severe intellectual deficiency (IQ < 50).
2. Psychoses judged to be secondary to medical illness, medication effects or drugs of
abuse.
3. Diagnosis of bipolar disorder.
4. Patients who are under legal guardianship.
5. For the neuroimaging part of the study only : any contraindications to Magnetic
Resonance Imaging.